These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22328963)

  • 1. Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity.
    Seo BI; Uchil VR; Okello M; Mishra S; Ma XH; Nishonov M; Shu Q; Chi G; Nair V
    ACS Med Chem Lett; 2011 Oct; 2(12):877-881. PubMed ID: 22328963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids.
    Nair V; Okello M
    Molecules; 2015 Jul; 20(7):12623-51. PubMed ID: 26184144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV.
    Schreier JD; Embrey MW; Raheem IT; Barbe G; Campeau LC; Dubost D; McCabe Dunn J; Grobler J; Hartingh TJ; Hazuda DJ; Klein D; Miller MD; Moore KP; Nguyen N; Pajkovic N; Powell DA; Rada V; Sanders JM; Sisko J; Steele TG; Wai J; Walji A; Xu M; Coleman PJ
    Bioorg Med Chem Lett; 2017 May; 27(9):2038-2046. PubMed ID: 28285916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.
    Anker M; Corales RB
    Expert Opin Investig Drugs; 2008 Jan; 17(1):97-103. PubMed ID: 18095922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
    Raheem IT; Walji AM; Klein D; Sanders JM; Powell DA; Abeywickrema P; Barbe G; Bennet A; Childers K; Christensen M; Clas SD; Dubost D; Embrey M; Grobler J; Hafey MJ; Hartingh TJ; Hazuda DJ; Kuethe JT; McCabe Dunn J; Miller MD; Moore KP; Nolting A; Pajkovic N; Patel S; Peng Z; Rada V; Rearden P; Schreier JD; Sisko J; Steele TG; Truchon JF; Wai J; Xu M; Coleman PJ
    J Med Chem; 2015 Oct; 58(20):8154-65. PubMed ID: 26397965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
    Podany AT; Scarsi KK; Pham MM; Fletcher CV
    Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
    Kobayashi M; Yoshinaga T; Seki T; Wakasa-Morimoto C; Brown KW; Ferris R; Foster SA; Hazen RJ; Miki S; Suyama-Kagitani A; Kawauchi-Miki S; Taishi T; Kawasuji T; Johns BA; Underwood MR; Garvey EP; Sato A; Fujiwara T
    Antimicrob Agents Chemother; 2011 Feb; 55(2):813-21. PubMed ID: 21115794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
    Kassahun K; McIntosh I; Cui D; Hreniuk D; Merschman S; Lasseter K; Azrolan N; Iwamoto M; Wagner JA; Wenning LA
    Drug Metab Dispos; 2007 Sep; 35(9):1657-63. PubMed ID: 17591678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH; Markowitz M
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.
    Walji AM; Sanchez RI; Clas SD; Nofsinger R; de Lera Ruiz M; Li J; Bennet A; John C; Bennett DJ; Sanders JM; Di Marco CN; Kim SH; Balsells J; Ceglia SS; Dang Q; Manser K; Nissley B; Wai JS; Hafey M; Wang J; Chessen G; Templeton A; Higgins J; Smith R; Wu Y; Grobler J; Coleman PJ
    ChemMedChem; 2015 Feb; 10(2):245-52. PubMed ID: 25469982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.
    Pandey KK; Bera S; Vora AC; Grandgenett DP
    Biochemistry; 2010 Sep; 49(38):8376-87. PubMed ID: 20799722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs).
    Ivashchenko AA; Ivanenkov YA; Koryakova AG; Karapetian RN; Mitkin OD; Aladinskiy VA; Kravchenko DV; Savchuk NP; Ivashchenko AV
    Eur J Med Chem; 2020 Mar; 189():112064. PubMed ID: 31972393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly approved integrase inhibitors for clinical treatment of AIDS.
    Gu WG
    Biomed Pharmacother; 2014 Oct; 68(8):917-21. PubMed ID: 25451165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
    Brainard DM; Wenning LA; Stone JA; Wagner JA; Iwamoto M
    J Clin Pharmacol; 2011 Oct; 51(10):1376-402. PubMed ID: 21209233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.